BR112015017242B1 - Uso de um anticorpo anti-flt-1 - Google Patents

Uso de um anticorpo anti-flt-1 Download PDF

Info

Publication number
BR112015017242B1
BR112015017242B1 BR112015017242-3A BR112015017242A BR112015017242B1 BR 112015017242 B1 BR112015017242 B1 BR 112015017242B1 BR 112015017242 A BR112015017242 A BR 112015017242A BR 112015017242 B1 BR112015017242 B1 BR 112015017242B1
Authority
BR
Brazil
Prior art keywords
flt
antibody
muscle
antigen
binding
Prior art date
Application number
BR112015017242-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015017242A2 (cg-RX-API-DMAC7.html
Inventor
Serene Josiah
Thomas M. Luby
Atsushi ASAKURA
Dennis Keefe
Lawrence Charnas
Mayank VERMA
Original Assignee
Regents Of The University Of Minnesota
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of The University Of Minnesota, Takeda Pharmaceutical Company Limited filed Critical Regents Of The University Of Minnesota
Publication of BR112015017242A2 publication Critical patent/BR112015017242A2/pt
Publication of BR112015017242B1 publication Critical patent/BR112015017242B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112015017242-3A 2013-01-28 2014-01-28 Uso de um anticorpo anti-flt-1 BR112015017242B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361757571P 2013-01-28 2013-01-28
US61/757,571 2013-01-28
PCT/US2014/013402 WO2014117160A1 (en) 2013-01-28 2014-01-28 Anti-flt-1 antibodies in treating duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
BR112015017242A2 BR112015017242A2 (cg-RX-API-DMAC7.html) 2017-08-15
BR112015017242B1 true BR112015017242B1 (pt) 2023-11-07

Family

ID=50073518

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017242-3A BR112015017242B1 (pt) 2013-01-28 2014-01-28 Uso de um anticorpo anti-flt-1

Country Status (14)

Country Link
US (3) US9957324B2 (cg-RX-API-DMAC7.html)
EP (1) EP2948476B1 (cg-RX-API-DMAC7.html)
JP (2) JP6469022B2 (cg-RX-API-DMAC7.html)
KR (1) KR102259255B1 (cg-RX-API-DMAC7.html)
CN (1) CN104955843B (cg-RX-API-DMAC7.html)
AU (1) AU2014209012B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015017242B1 (cg-RX-API-DMAC7.html)
CA (1) CA2898998C (cg-RX-API-DMAC7.html)
EA (1) EA037501B1 (cg-RX-API-DMAC7.html)
ES (1) ES2676406T3 (cg-RX-API-DMAC7.html)
HK (1) HK1213918A1 (cg-RX-API-DMAC7.html)
IL (1) IL238588B (cg-RX-API-DMAC7.html)
MX (1) MX360153B (cg-RX-API-DMAC7.html)
WO (1) WO2014117160A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948164B1 (en) 2013-01-28 2019-04-10 Shire Human Genetic Therapies, Inc. Placenta growth factor in treating duchenne muscular dystrophy
MA41899A (fr) * 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne
US10738123B2 (en) 2015-04-07 2020-08-11 Shire Human Genetic Therapies, Inc. Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
CA2981961A1 (en) * 2015-04-07 2016-10-13 Shire Human Genetic Therapies, Inc. Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
WO2023182657A1 (ko) 2022-03-24 2023-09-28 주식회사 케이에스비튜젠 항-fetuin-b 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377555A3 (en) * 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1

Also Published As

Publication number Publication date
IL238588B (en) 2020-04-30
CA2898998C (en) 2023-02-14
EP2948476B1 (en) 2018-06-06
AU2014209012B2 (en) 2018-11-08
EA037501B1 (ru) 2021-04-05
EA201590720A1 (ru) 2015-11-30
EP2948476A1 (en) 2015-12-02
WO2014117160A1 (en) 2014-07-31
ES2676406T3 (es) 2018-07-19
HK1217710A1 (en) 2017-01-20
JP6469022B2 (ja) 2019-02-13
IL238588A0 (en) 2015-06-30
US20150361174A1 (en) 2015-12-17
BR112015017242A2 (cg-RX-API-DMAC7.html) 2017-08-15
CN104955843B (zh) 2019-08-13
JP2019023230A (ja) 2019-02-14
US20180312593A1 (en) 2018-11-01
EA201590720A8 (ru) 2018-09-28
AU2014209012A1 (en) 2015-05-21
JP2016511234A (ja) 2016-04-14
CN104955843A (zh) 2015-09-30
KR20150109386A (ko) 2015-10-01
US9957324B2 (en) 2018-05-01
US20210163603A1 (en) 2021-06-03
KR102259255B1 (ko) 2021-05-31
MX2015009690A (es) 2016-03-31
CA2898998A1 (en) 2014-07-31
MX360153B (es) 2018-10-24
HK1213918A1 (zh) 2016-07-15

Similar Documents

Publication Publication Date Title
US20210163603A1 (en) Anti-flt-1 antibodies in treating duchenne muscular dystrophy
JP6475639B2 (ja) デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン
JP7456989B2 (ja) デュシェンヌ型筋ジストロフィーの治療における抗flt-1抗体
JP2020519291A (ja) 組み換えフォリスタチン−fc融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用
JP2019509735A (ja) デュシェンヌ型筋ジストロフィー治療における組換えフォリスタチン−Fc融合タンパク質及び使用
US20150368309A1 (en) Placenta growth factor in treating duchenne muscular dystrophy
HK1217710B (en) Anti-flt-1 antibodies in treating duchenne muscular dystrophy
Muñoz-Beamud et al. 2021 peripheral nerve society virtual event
BR122024023570A2 (pt) Polinucleotídeo que codifica um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno, composição farmacêutica, usos relacionados, vetor de expressão, célula isolada e anticorpos anti-flt-1 ou seu fragmento de ligação ao antígeno
BR112017021414B1 (pt) Anticorpos anti-flt-1 e composição farmacêutica compreendendo os referidos anticorpos
Kao et al. 302 LATERALLY WEDGED SHOE INSERTS AS AN INTERVENTION FOR MEDIAL KNEE OSTEOARTHRITIS.
Wang et al. 304 AUTOIMMUNE DISEASE MANIFEST BY CUTANEOUS LESIONS IN A PEDIATRIC PATIENT WITH CROHN'S DISEASE TREATED BY INFLIXIMAB.
HK1213804B (en) Follistatin in treating duchenne muscular dystrophy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: REGENTS OF THE UNIVERSITY OF MINNESOTA (US) ; TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2014, OBSERVADAS AS CONDICOES LEGAIS